Market Overview the Global Angina Pectoris Market had a valuation of USD 2.46 billion in 2022, and it is anticipated to reach USD 10.36 billion by 2032. During the forecast period, the market is expected to experience a revenue compound annual growth rate (CAGR) of 4.6%. Key factors driving this growth include the increasing prevalence of angina pectoris due to factors such as an aging population, changing lifestyles, heart diseases, and related conditions.
Key Players: Major companies in the angina pectoris market include AstraZeneca, Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb Company, and Boehringer Ingelheim International GmbH.
Angina Pectoris Prevalence Angina pectoris, a cardiovascular condition, affects millions of people worldwide. It manifests as chest discomfort or soreness when the heart muscle doesn’t receive an adequate supply of blood and oxygen.
Factors Behind Rising Angina Pectoris Cases The rise in angina pectoris cases can be attributed to the growing prevalence of sedentary lifestyles, poor dietary habits, and inadequate physical activity. According to the World Health Organization (WHO), cardiovascular disorders are responsible for 17.9 million fatalities annually, making them a leading global cause of mortality. Additionally, increased occurrences of risk factors such as obesity, diabetes, hypertension, and high cholesterol levels are contributing to the market’s revenue growth.
Get a sample copy of the Angina Pectoris Market report: https://www.reportsanddata.com/download-free-sample/5779
Government and Healthcare Initiatives Government and healthcare organizations are increasingly focused on improving patient outcomes and reducing the burden of cardiovascular diseases. Initiatives like the American Heart Association’s Go Red for Women campaign and the International Heart Federation’s World Heart Day aim to raise public awareness of heart diseases and promote early detection and treatment.
Global Expansion of Treatment The rising demand for angina pectoris treatments in developing countries, such as India, China, and Brazil, is contributing to market growth. The growing healthcare infrastructure and increasing healthcare costs in these countries are expected to drive market expansion.
Challenges Despite the positive outlook, high treatment costs, adverse drug side effects, and lack of disease awareness in some regions may hinder market revenue growth.
Government Regulations Government bodies like the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Medicare & Medicaid Services (CMS), the American Heart Association, and the World Health Organization have established regulations and guidelines for the diagnosis, treatment, and management of angina pectoris.
Key Insights Type Classification: The market distinguishes between stable and unstable angina. In 2022, the Stable Angina category held a significant revenue share. Stable angina occurs when the heart is under increased stress, such as during physical exertion or mental stress, and it is characterized by consistent symptoms. The rising prevalence of cardiovascular diseases and increasing healthcare costs are expected to drive the growth of treatments for stable angina.
Unstable Angina: Unstable angina, which is sudden and unpredictable, is expected to experience the fastest revenue growth throughout the forecast period. It is a more severe condition than stable angina, and immediate medical treatment is required as its symptoms are more acute and can occur at rest.
Clinics: The clinics segment is anticipated to witness significant growth due to the increasing prevalence of angina pectoris and the demand for more affordable treatment options.
Other End-Users: The “other” category, which includes ambulatory surgical facilities, diagnostic facilities, and cardiac rehabilitation facilities, is expected to grow moderately as the demand for specialized services in angina pectoris treatment rises.
Regional Analysis: North America led the global market in 2022, driven by a high prevalence of cardiovascular diseases, strong healthcare infrastructure, and good reimbursement policies. The Asia Pacific region is expected to experience the fastest revenue growth due to factors like an aging population and increasing healthcare costs in developing nations.
- Type Outlook:
- Stable Angina
- Unstable Angina
- Treatment Outlook:
- Medication
- Surgery
- Others
- End-Use Outlook:
- Hospitals
- Clinics
- Others
- Regional Scope:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Key Companies Profiled:
- AstraZeneca
- Bayer AG
- Gilead Sciences Inc
- Merck & Co. Inc
- Pfizer Inc
- Sanofi S.A
- Novartis International AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
Explore Trending Reports:
Histology and Cytology Market-https://www.globenewswire.com/news-release/2019/11/14/1947433/0/en/Histology-and-Cytology-Market-To-Reach-USD-30-543-4-Million-By-2026-Reports-And-Data.html
Retinal Surgery Devices Market-https://www.globenewswire.com/news-release/2019/12/05/1957037/0/en/Retinal-Surgery-Devices-Market-To-Reach-USD-3-27-Billion-By-2026-Reports-And-Data.html
Virus Filtration Market-https://www.globenewswire.com/news-release/2020/05/13/2032800/0/en/Virus-Filtration-Market-To-Reach-USD-4-11-Billion-By-2027-Reports-and-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5779
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release